A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Administration of SCAI-005 Ophthalmic Solution in Healthy Korean Subjects
Latest Information Update: 21 May 2025
At a glance
- Drugs Axitinib (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors SCAI Therapeutics
Most Recent Events
- 21 May 2025 New trial record